BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 15327647)

  • 1. In vitro activity of moxifloxacin compared to other antimicrobials against streptococci isolated from iatrogenic oral bacteremia in Spain.
    Tomás I; Alvarez M; Limeres J; Otero JL; Saavedra E; López-Meléndez C; Diz P
    Oral Microbiol Immunol; 2004 Oct; 19(5):331-5. PubMed ID: 15327647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viridans streptococci in endocarditis and neutropenic sepsis: biofilm formation and effects of antibiotics.
    Presterl E; Grisold AJ; Reichmann S; Hirschl AM; Georgopoulos A; Graninger W
    J Antimicrob Chemother; 2005 Jan; 55(1):45-50. PubMed ID: 15563519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacies of amoxicillin, clindamycin, and moxifloxacin in prevention of bacteremia following dental extractions.
    Diz Dios P; Tomás Carmona I; Limeres Posse J; Medina Henríquez J; Fernández Feijoo J; Alvarez Fernández M
    Antimicrob Agents Chemother; 2006 Sep; 50(9):2996-3002. PubMed ID: 16940094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman MA; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jun; 55(2):119-27. PubMed ID: 16530373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E; Dalhoff A; Korfmann G
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
    Gosbell IB; Fernandes LA; Fernandes CJ
    Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies in antibiotic choices for odontogenic infections.
    Stefanopoulos PK; Kolokotronis AE
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jun; 101(6):697-8. PubMed ID: 16731384
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
    Amábile-Cuevas CF; Hermida-Escobedo C; Vivar R
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S30-2. PubMed ID: 11249826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical antimicrobial therapy for odontogenic infections.
    Limeres J; Tomás I; Alvarez M; Diz P
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Sep; 100(3):263-4. PubMed ID: 16122650
    [No Abstract]   [Full Text] [Related]  

  • 11. [In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].
    Rodríguez-Avial I; Rodríguez-Avial C; Picazo JJ
    Rev Esp Quimioter; 2001 Dec; 14(4):364-8. PubMed ID: 11856983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence rate and antibiotic susceptibility of oral viridans group streptococci (VGS) in healthy children population.
    Rozkiewicz D; Daniluk T; Sciepuk M; Zaremba ML; Cylwik-Rokicka D; Luczaj-Cepowicz E; Milewska R; Marczuk-Kolada G; Stokowska W
    Adv Med Sci; 2006; 51 Suppl 1():191-5. PubMed ID: 17460837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of the new quinolone WCK 771 against pneumococci.
    Appelbaum PC; Pankuch GA; Bozdogan B; Lin G; Jacobs MR; Patel MV; Gupte SV; Jafri MA; De Souza NJ; Khorakiwala HF
    Clin Microbiol Infect; 2005 Jan; 11(1):9-14. PubMed ID: 15649298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Odontogenic bacteria in periodontal disease and resistance patterns to common antibiotics used as treatment and prophylaxis in odontology in Spain.
    Maestre JR; Bascones A; Sánchez P; Matesanz P; Aguilar L; Giménez MJ; Pérez-Balcabao I; Granizo JJ; Prieto J
    Rev Esp Quimioter; 2007 Mar; 20(1):61-7. PubMed ID: 17530037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003.
    Johnson AP; Lamagni TL; Wale M; Cavendish S; Bishop L; Alhaddad N; Warner M; Livermore DM; Duckworth G; George RC
    Int J Antimicrob Agents; 2005 Jun; 25(6):539-41. PubMed ID: 15890501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility testing of Streptococcus mitis group isolates.
    Bancescu G; Dumitriu S; Bancescu A; Defta C; Pana M; Ionescu D; Alecu S; Zamfirescu M
    Indian J Med Res; 2004 May; 119 Suppl():257-61. PubMed ID: 15232207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
    Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece.
    Papaparaskevas J; Pantazatou A; Katsandri A; Houhoula DP; Legakis NJ; Tsakris A; Avlamis A
    J Antimicrob Chemother; 2008 Jul; 62(1):137-41. PubMed ID: 18385145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.